Please login to the form below

Not currently logged in
Email:
Password:

Neurocentrx appoints two members to the board

Nigel Brooksby and Dr Tim Corn join the pharma group

Nigel BrooksbyNeurocentrx, a UK-based pharmaceutical company, has appointed Nigel Brooksby (pictured right) as non-executive chairman.

Brooksby brings experience in business and growth strategy across the healthcare sector having held senior global positions at Pfizer, Sanofi and Wellcome - now GSK.

His career history has seen him work in private equity and venture capital and he has been president of the ABPI.

Brooksby said: “My focus is to accelerate the business model and drive commercial clinical trials to raise international awareness of what we are offering, and enter the global market.

“I look forward to working the team, and helping to drive the company to an exciting new stage in their development.”

Joining Brooksby is EUSA Pharma’s former chief medical officer Dr Tim Corn, who becomes the pharma group’s non-executive director.

Carmel Reilly, chief executive officer of Neurocentrx, said: “I am honoured to welcome the extraordinary talents of Nigel and Tim onto the board.

“This is an important milestone for Neurocentrx and marks the start of an exciting new phase of our growth.”

13th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics